Clinical trial
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in…
NCT05238883 · HiFiBiO Therapeutics, Industry · Active, not recruiting
Key facts
| NCT number | NCT05238883 |
|---|---|
| Title | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors |
| Official title | A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors |
| Lead sponsor | HiFiBiO Therapeutics, Industry |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma |
| Intervention type | Drug |
| Interventions | HFB200301, Tislelizumab |
| Enrollment | 72 |
| Start date | Mar 10, 2022 |
| Primary completion | Dec 1, 2026 |
| Completion | Dec 1, 2026 |
| First posted | Feb 14, 2022 |
| Last update posted | Nov 21, 2025 |
| Countries | Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: